{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:30:16Z","timestamp":1794886216234,"version":"4.9.1"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10787-025-02104-2","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:02:30Z","timestamp":1768006950000},"page":"811-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Narrative review on the development of multi-target pharmacological agents for the management of rheumatoid arthritis"],"prefix":"10.1007","volume":"34","author":[{"given":"Yarava","family":"Dhanush","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vakkalagadda Siva","family":"Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"issue":"6","key":"2104_CR65","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40259-014-0098-x","volume":"28","author":"S Adami","year":"2014","unstructured":"Adami S, Cavani A, Rossi F, Girolomoni G (2014) The role of interleukin-17A in psoriatic disease. BioDrugs 28(6):487\u2013497","journal-title":"BioDrugs"},{"issue":"2","key":"2104_CR82","doi-asserted-by":"publisher","first-page":"951","DOI":"10.4049\/jimmunol.1003986","volume":"187","author":"IE Adamopoulos","year":"2011","unstructured":"Adamopoulos IE, Tessmer M, Chao CC, Adda S, Gorman D, Petro M et al (2011) IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol 187(2):951\u2013959","journal-title":"J Immunol"},{"issue":"3","key":"2104_CR68","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1074\/jbc.M207577200","volume":"278","author":"S Aggarwal","year":"2003","unstructured":"Aggarwal S, Ghilardi N, Xie MH, De Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278(3):1910\u20131914","journal-title":"J Biol Chem"},{"issue":"3","key":"2104_CR88","first-page":"90","volume":"47","author":"A Ahmad","year":"2024","unstructured":"Ahmad A, Zaheer M, Balis FJ (2024) Baricitinib. Med Monatsschr Pharm 47(3):90\u201396","journal-title":"Med Monatsschr Pharm"},{"key":"2104_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom10071002","volume":"10","author":"J Angelini","year":"2020","unstructured":"Angelini J, Talotta R, Roncato R, Fornasier G, Barbiero G, Cin LD et al (2020) JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules 10:1\u201340","journal-title":"Biomolecules"},{"key":"2104_CR58","doi-asserted-by":"crossref","unstructured":"Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ et al (2000) Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 43","DOI":"10.1002\/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO;2-S"},{"issue":"3","key":"2104_CR105","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.clim.2011.12.012","volume":"142","author":"PM Barr","year":"2012","unstructured":"Barr PM, Wei C, Roger J, Schaefer-Cutillo J, Kelly JL, Rosenberg AF et al (2012) Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. Clin Immunol 142(3):237","journal-title":"Clin Immunol"},{"key":"2104_CR46","doi-asserted-by":"crossref","unstructured":"Ba X, Huang Y, Shen P, Huang Y, Wang H, Han L et al (2021) WTD attenuating rheumatoid arthritis via suppressing angiogenesis and modulating the PI3K\/AKT\/mTOR\/HIF-1\u03b1 pathway. Front Pharmacol 12","DOI":"10.3389\/fphar.2021.696802"},{"issue":"11","key":"2104_CR96","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","volume":"77","author":"HA Blair","year":"2017","unstructured":"Blair HA, Deeks ED (2017) Abatacept: a review in rheumatoid arthritis. Drugs 77(11):1221\u20131233","journal-title":"Drugs"},{"issue":"11","key":"2104_CR98","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1002\/art.38094","volume":"65","author":"M Blits","year":"2013","unstructured":"Blits M, Jansen G, Assaraf YG, Van De Wiel MA, Lems WF, Nurmohamed MT et al (2013) Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum 65(11):2791\u20132802","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2104_CR81","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/ijms19020530","volume":"19","author":"MA Boutet","year":"2018","unstructured":"Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C (2018) Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci 19(2):530","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2104_CR95","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/1060028018761599","volume":"52","author":"EG Boyce","year":"2018","unstructured":"Boyce EG, Rogan EL, Vyas D, Prasad N, Mai Y (2018) Sarilumab: review of a second IL-6 receptor antagonist indicated for the treatment of rheumatoid arthritis. Ann Pharmacother 52(8):780\u2013791","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2104_CR84","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/annonc\/mdg175","volume":"14","author":"J Boye","year":"2003","unstructured":"Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14(4):520\u2013535","journal-title":"Ann Oncol"},{"issue":"11","key":"2104_CR100","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/ard.59.11.841","volume":"59","author":"FC Breedveld","year":"2000","unstructured":"Breedveld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59(11):841\u2013849","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2104_CR110","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/rheumatology\/kem075","volume":"46","author":"M Buch","year":"2007","unstructured":"Buch M, Bingham S, Bryer D, Emery P (2007) Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology 46(7):1153","journal-title":"Rheumatology"},{"key":"2104_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000493390","volume":"27","author":"J Bullock","year":"2019","unstructured":"Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA et al (2019) Rheumatoid arthritis: a brief overview of the treatment. Med Princ Pract 27:501\u2013507","journal-title":"Med Princ Pract"},{"issue":"10086","key":"2104_CR120","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","volume":"389","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Pope JE (2017) Novel treatment strategies in rheumatoid arthritis. Lancet 389(10086):2338\u20132348","journal-title":"Lancet"},{"key":"2104_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128889","author":"AN Burska","year":"2015","unstructured":"Burska AN, Sakthiswary R, Sattar N (2015) Effects of tumour necrosis factor antagonists on insulin sensitivity\/resistance in rheumatoid arthritis: a systematic review and meta-analysis. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0128889","journal-title":"PLoS ONE"},{"issue":"5","key":"2104_CR14","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.4103\/jfmpc.jfmpc_307_20","volume":"9","author":"N Chaurasia","year":"2020","unstructured":"Chaurasia N, Singh A, Singh I, Singh T, Tiwari T (2020) Cognitive dysfunction in patients of rheumatoid arthritis. J Family Med Prim Care 9(5):2219","journal-title":"J Family Med Prim Care"},{"issue":"7","key":"2104_CR43","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1136\/annrheumdis-2014-207178","volume":"75","author":"CS Christina","year":"2016","unstructured":"Christina CS, Burmester G, Nash P, Zerbini CAF, Soma K, Kwok K et al (2016) Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis 75(7):1293\u20131301","journal-title":"Ann Rheum Dis"},{"key":"2104_CR56","unstructured":"Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor \u03b1 in synovial tissues and at the rheumatoid arthritis cartilage-pannus junction in patients with"},{"issue":"Suppl 2","key":"2104_CR116","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa895","volume":"60","author":"B Clarke","year":"2021","unstructured":"Clarke B, Yates M, Adas M, Bechman K, Galloway J (2021) The safety of JAK-1 inhibitors. Rheumatology 60(Suppl 2):ii24","journal-title":"Rheumatology"},{"key":"2104_CR9","volume":"5","author":"M Cojocaru","year":"2010","unstructured":"Cojocaru M, Mihaela Cojocaru I, Silosi I, Doina Vrabie C, Tanasescu R (2010) Extra-articular manifestations in rheumatoid arthritis. Maedica J Clin Med 5:286","journal-title":"Maedica J Clin Med"},{"issue":"5","key":"2104_CR91","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00063030-200620050-00005","volume":"20","author":"RS Cvetkovi\u0107","year":"2006","unstructured":"Cvetkovi\u0107 RS, Scott LJ (2006) Adalimumab: a review of its use in adult patients with rheumatoid arthritis. BioDrugs 20(5):293\u2013311","journal-title":"BioDrugs"},{"issue":"6","key":"2104_CR57","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1084\/jem.162.6.2163","volume":"162","author":"JM Dayer","year":"1985","unstructured":"Dayer JM, Beutler B, Cerami A (1985) Cachectin\/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162(6):2163\u20132168","journal-title":"J Exp Med"},{"issue":"11","key":"2104_CR76","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1002\/art.22175","volume":"54","author":"F De Benedetti","year":"2006","unstructured":"De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M et al (2006) Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 54(11):3551\u20133563","journal-title":"Arthritis Rheum"},{"key":"2104_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/ar4555","volume":"16","author":"G Dennis Jr","year":"2014","unstructured":"Dennis G Jr, Holweg CT, Kummerfeld SK, Choy DF, Francesca Setiadi A, Hackney JA et al (2014) Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther 16:R90","journal-title":"Arthritis Res Ther"},{"key":"2104_CR104","unstructured":"Denosumab (Prolia). https:\/\/rheumatology.org\/patients\/denosumab-prolia"},{"issue":"18","key":"2104_CR87","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon S (2017) Tofacitinib: a review in rheumatoid arthritis. Drugs 77(18):1987\u20132001","journal-title":"Drugs"},{"key":"2104_CR21","doi-asserted-by":"crossref","unstructured":"Ding Q, Hu W, Wang R, Yang Q, Zhu M, Li M et al (2023) Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct Target Ther 8","DOI":"10.1038\/s41392-023-01331-9"},{"issue":"10","key":"2104_CR2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.114.009990","volume":"130","author":"A Dregan","year":"2014","unstructured":"Dregan A, Charlton J, Chowienczyk P, Gulliford MC (2014) Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation 130(10):837\u2013844","journal-title":"Circulation"},{"key":"2104_CR47","doi-asserted-by":"crossref","unstructured":"Du H, Zhang X, Zeng Y, Huang X, Chen H, Wang S et al (2019) A novel phytochemical, DIM, inhibits proliferation, migration, invasion and TNF-\u03b1 induced inflammatory cytokine production of synovial fibroblasts from rheumatoid arthritis patients by targeting MAPK and AKT\/mTOR signal pathway. Front Immunol 10","DOI":"10.3389\/fimmu.2019.01620"},{"key":"2104_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188881","author":"I Elisia","year":"2017","unstructured":"Elisia I, Lam V, Hofs E, Li MY, Hay M, Cho B et al (2017) Effect of age on chronic inflammation and responsiveness to bacterial and viral challenges. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0188881","journal-title":"PLoS ONE"},{"key":"2104_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173238","author":"T Emori","year":"2020","unstructured":"Emori T, Kasahara M, Sugahara S, Hashimoto M, Ito H, Narumiya S et al (2020) Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: effect of the novel JAK inhibitor peficitinib. Eur J Pharmacol. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173238","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"2104_CR62","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.orthres.2004.10.004","volume":"23","author":"NJ Epstein","year":"2005","unstructured":"Epstein NJ, Warme BA, Spanogle J, Ma T, Bragg B, Smith RL et al (2005) Interleukin-1 modulates periprosthetic tissue formation in an intramedullary model of particle-induced inflammation. J Orthop Res 23(3):501\u2013510","journal-title":"J Orthop Res"},{"key":"2104_CR28","doi-asserted-by":"crossref","unstructured":"Fanger GR, Johnson NL, Johnson GL (1997) MEK kinases are regulated by EGF and selectively interact with Rac\/Cdc42 Raf which regulates the ERK pathway. EMBO J 16","DOI":"10.1093\/emboj\/16.16.4961"},{"issue":"6937","key":"2104_CR83","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature01661","volume":"423","author":"GS Firestein","year":"2003","unstructured":"Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423(6937):356\u2013361","journal-title":"Nature"},{"key":"2104_CR52","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","volume":"46","author":"GS Firestein","year":"2017","unstructured":"Firestein GS, McInnes IB (2017a) Immunopathogenesis of rheumatoid arthritis. Immunity 46:183\u2013196","journal-title":"Immunity"},{"issue":"2","key":"2104_CR121","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","volume":"46","author":"GS Firestein","year":"2017","unstructured":"Firestein GS, McInnes IB (2017b) Immunopathogenesis of rheumatoid arthritis. Immunity 46(2):183\u2013196","journal-title":"Immunity"},{"issue":"2","key":"2104_CR55","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1517\/14712598.2.2.135","volume":"2","author":"C Gabay","year":"2002","unstructured":"Gabay C, Kushner I (2002) Cytokine inhibitors in the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2(2):135\u2013149","journal-title":"Expert Opin Biol Ther"},{"key":"2104_CR90","doi-asserted-by":"crossref","unstructured":"Gholami A, Azizpoor J, Aflaki E, Rezaee M, Keshavarz K (2021) Cost-effectiveness analysis of biopharmaceuticals for treating rheumatoid arthritis: Infliximab, adalimumab, and etanercept. Biomed Res Int 2021","DOI":"10.1155\/2021\/4450162"},{"key":"2104_CR106","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ, Provan D, B\u00e1rez A, Bernardo-Guti\u00e9rrez A, Bernat S, Mart\u00ednez-Carballeira D et al (2023) Primary and secondary immune thrombocytopenia (ITP): Time for a rethink. Blood Rev 61","DOI":"10.1016\/j.blre.2023.101112"},{"issue":"3","key":"2104_CR60","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1302\/0301-620X.80B3.0800531","volume":"80","author":"SB Goodman","year":"1998","unstructured":"Goodman SB, Huie P, Song Y, Schurman D, Maloney W, Woolson S et al (1998) Cellular profile and cytokine production at prosthetic interfaces. Study of tissues retrieved from revised hip and knee replacements. J Bone Joint Surg Br 80(3):531\u2013539","journal-title":"J Bone Joint Surg Br"},{"issue":"3","key":"2104_CR115","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/art.30194","volume":"63","author":"MW Greenwald","year":"2011","unstructured":"Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD (2011) Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum 63(3):622\u2013632","journal-title":"Arthritis Rheum"},{"key":"2104_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-11-14","volume":"11","author":"D Hammaker","year":"2014","unstructured":"Hammaker D, Boyle DL, Topolewski K, Firestein GS (2014) Differential regulation of anti-inflammatory genes by p38 MAP kinase and MAP kinase kinase 6. J Inflamm 11:14","journal-title":"J Inflamm"},{"issue":"10","key":"2104_CR32","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr2.11093","volume":"1","author":"D Hammaker","year":"2019","unstructured":"Hammaker D, Nygaard G, Kuhs A, Ai R, Boyle DL, Wang W et al (2019) Joint location\u2013specific JAK-STAT signaling in rheumatoid arthritis fibroblast-like synoviocytes. ACR Open Rheumatol 1(10):640\u2013648","journal-title":"ACR Open Rheumatol"},{"issue":"6","key":"2104_CR30","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1084\/jem.20040852","volume":"201","author":"S Hayer","year":"2005","unstructured":"Hayer S, Steiner G, G\u00f6rtz B, Reiter E, Tohidast-Akrad M, Amling M et al (2005) CD44 is a determinant of inflammatory bone loss. J Exp Med 201(6):903\u2013914","journal-title":"J Exp Med"},{"issue":"4","key":"2104_CR59","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2106\/00004623-199604000-00002","volume":"78","author":"DG Hicks","year":"1996","unstructured":"Hicks DG, Judkins AR, Sickel JZ, Rosier RN, Puzas JE, O\u2019Keefe RJ (1996) Granular histiocytosis of pelvic lymph nodes following total hip arthroplasty. The presence of wear debris, cytokine production, and immunologically activated macrophages. J Bone Joint Surg Am 78(4):482\u2013496","journal-title":"J Bone Joint Surg Am"},{"key":"2104_CR16","unstructured":"Hoque M, Saha SN, Akram T (2023) A review on methotrexate used in rheumatoid arthritis. Int J Res"},{"key":"2104_CR31","doi-asserted-by":"crossref","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W (2021) The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther","DOI":"10.1038\/s41392-021-00791-1"},{"key":"2104_CR118","doi-asserted-by":"crossref","unstructured":"Inotai A, Tomek D, Niewada M, Lorenzovici L, Kolek M, Weber J et al (2020) Identifying patient access barriers for tumor necrosis factor alpha inhibitor treatments in rheumatoid arthritis in five Central Eastern European countries. Front Pharmacol 11","DOI":"10.3389\/fphar.2020.00845"},{"key":"2104_CR85","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50025","author":"P Johnson","year":"2003","unstructured":"Johnson P, Glennie MJ (2003) The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. https:\/\/doi.org\/10.1053\/sonc.2003.50025","journal-title":"Semin Oncol"},{"issue":"11","key":"2104_CR86","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1054\/bjoc.2001.2127","volume":"85","author":"PWM Johnson","year":"2001","unstructured":"Johnson PWM, Glennie MJ (2001) Rituximab: mechanisms and applications. Br J Cancer 85(11):1619","journal-title":"Br J Cancer"},{"key":"2104_CR70","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/263625","volume":"2014","author":"SM Jung","year":"2014","unstructured":"Jung SM, Kim KW, Yang CW, Park SH, Ju JH, Mamura M (2014) Cytokine-mediated bone destruction in rheumatoid arthritis. J Immunol Res 2014:263625","journal-title":"J Immunol Res"},{"issue":"3","key":"2104_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/ard.2003.013276","volume":"63","author":"PV Kasperkovitz","year":"2004","unstructured":"Kasperkovitz PV, Verbeet NL, Smeets TJ, Van Rietschoten JGI, Kraan MC, Van Der Pouw KTCTM et al (2004) Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis 63(3):233\u2013239","journal-title":"Ann Rheum Dis"},{"key":"2104_CR109","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099861","author":"W Katchamart","year":"2009","unstructured":"Katchamart W, Trudeau J, Phumethum V, Bombardier C (2009) Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard.2008.099861","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2104_CR38","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","volume":"76","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M et al (2017) Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis 76(6):1009\u20131019","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2104_CR73","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1084\/jem.20050978","volume":"202","author":"N Kim","year":"2005","unstructured":"Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F et al (2005) Osteoclast differentiation independent of the TRANCE\u2013RANK\u2013TRAF6 axis. J Exp Med 202(5):589","journal-title":"J Exp Med"},{"issue":"6","key":"2104_CR77","first-page":"1682","volume":"147","author":"H Kitamura","year":"1995","unstructured":"Kitamura H, Kawata H, Takahashi F, Higuchi Y, Furuichi T, Ohkawa H (1995) Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. Am J Pathol 147(6):1682\u20131692","journal-title":"Am J Pathol"},{"issue":"12","key":"2104_CR74","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1172\/JCI26132","volume":"115","author":"H Kitaura","year":"2005","unstructured":"Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL (2005) M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 115(12):3418\u20133427","journal-title":"J Clin Invest"},{"key":"2104_CR13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.5114\/ceji.2017.72807","volume":"42","author":"W Kurowska","year":"2017","unstructured":"Kurowska W, Kuca-Warnawin EH, Radzikowska A, Maslinski W (2017) The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Cent Eur J Immunol 42:390\u2013398","journal-title":"Cent Eur J Immunol"},{"issue":"4","key":"2104_CR66","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.4049\/jimmunol.162.4.2347","volume":"162","author":"M Laan","year":"1999","unstructured":"Laan M, Cui ZH, Hoshino H, L\u00f6tvall J, Sj\u00f6strand M, Gruenert DC, Skoogh BE, Lind\u00e9n A (1999) Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 162(4):2347\u20132352","journal-title":"J Immunol"},{"issue":"12","key":"2104_CR72","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1172\/JCI11176","volume":"106","author":"J Lam","year":"2000","unstructured":"Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL (2000) TNF-\u03b1 induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106(12):1481\u20131488","journal-title":"J Clin Invest"},{"issue":"2","key":"2104_CR67","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201(2):233\u2013240","journal-title":"J Exp Med"},{"issue":"22","key":"2104_CR24","doi-asserted-by":"publisher","first-page":"7802","DOI":"10.1128\/MCB.22.22.7802-7811.2002","volume":"22","author":"M Lasa","year":"2002","unstructured":"Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR (2002) Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 22(22):7802\u20137811","journal-title":"Mol Cell Biol"},{"issue":"10","key":"2104_CR75","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/intimm\/dxq431","volume":"22","author":"YM Lee","year":"2010","unstructured":"Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y (2010) IL-1 plays an important role in the bone metabolism under physiological conditions. Int Immunol 22(10):805\u2013816","journal-title":"Int Immunol"},{"issue":"9","key":"2104_CR113","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","volume":"28","author":"MJ Lewis","year":"2019","unstructured":"Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA et al (2019) Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep 28(9):2455-2470.e5","journal-title":"Cell Rep"},{"issue":"1","key":"2104_CR79","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/ar1478","volume":"7","author":"E Lubberts","year":"2005","unstructured":"Lubberts E, Koenders M, van den Berg WB (2005) The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 7(1):29\u201337","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2104_CR80","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.4049\/jimmunol.170.5.2655","volume":"170","author":"E Lubberts","year":"2003","unstructured":"Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJJ, Kolls JK et al (2003) IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand\/osteoprotegerin balance. J Immunol 170(5):2655\u20132662","journal-title":"J Immunol"},{"key":"2104_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1133828","volume":"13","author":"J Lu","year":"2023","unstructured":"Lu J, Hu D, Zhang Y, Ma C, Shen L, Shuai B (2023) Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials. Front Oncol 13:1133828","journal-title":"Front Oncol"},{"issue":"8","key":"2104_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081648","volume":"14","author":"A Madrid-Paredes","year":"2022","unstructured":"Madrid-Paredes A, Mart\u00edn J, M\u00e1rquez A (2022) -omic approaches and treatment response in rheumatoid arthritis. Pharmaceutics 14(8):1648","journal-title":"Pharmaceutics"},{"key":"2104_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1759720X18776224","volume":"10","author":"CJ Malemud","year":"2018","unstructured":"Malemud CJ (2018a) The role of the JAK\/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis 10:117\u2013127","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5\u20136","key":"2104_CR111","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1759720X18776224","volume":"10","author":"CJ Malemud","year":"2018","unstructured":"Malemud CJ (2018b) The role of the JAK\/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis 10(5\u20136):117","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"23","key":"2104_CR50","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205\u20132219 https:\/\/doi.org\/10.1056\/NEJMra1004965","journal-title":"N Engl J Med"},{"issue":"10086","key":"2104_CR108","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Schett G (2017) Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389(10086):2328\u20132337","journal-title":"Lancet"},{"key":"2104_CR114","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211002682","volume":"13","author":"A Migliore","year":"2021","unstructured":"Migliore A, Pompilio G, Integlia D, Zhuo J, Alemao E (2021) Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. Ther Adv Musculoskelet Dis 13:1759720X211002682","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2104_CR97","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/DDDT.S41645","volume":"8","author":"CC Mok","year":"2013","unstructured":"Mok CC (2013) Rituximab for the treatment of rheumatoid arthritis: an update. Drug des Devel Ther 8:87\u2013100","journal-title":"Drug des Devel Ther"},{"issue":"11","key":"2104_CR40","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/intimm\/dxr077","volume":"23","author":"T Mori","year":"2011","unstructured":"Mori T, Miyamoto T, Yoshida H, Asakawa M, Kawasumi M, Kobayashi T et al (2011) IL-1\u03b2 and TNF\u03b1-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 23(11):701\u2013712","journal-title":"Int Immunol"},{"issue":"1","key":"2104_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.mad.2014.06.005","volume":"139","author":"V Morrisette-Thomas","year":"2014","unstructured":"Morrisette-Thomas V, Cohen AA, F\u00fcl\u00f6p T, Riesco \u00c9, Legault V, Li Q et al (2014) Inflamm-aging does not simply reflect increases in pro-inflammatory markers. Mech Ageing Dev 139(1):49\u201357","journal-title":"Mech Ageing Dev"},{"key":"2104_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113017","author":"AL Mueller","year":"2021","unstructured":"Mueller AL, Payandeh Z, Mohammadkhani N, Mubarak SMH, Zakeri A, Bahrami AA et al (2021) Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies. Cells. https:\/\/doi.org\/10.3390\/cells10113017","journal-title":"Cells"},{"issue":"4","key":"2104_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/annrheumdis-2019-216694","volume":"79","author":"E Myasoedova","year":"2020","unstructured":"Myasoedova E, Davis J, Matteson EL, Crowson CS (2020) Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985\u20132014. Ann Rheum Dis 79(4):440\u2013444","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2104_CR69","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1006\/bbrc.2000.3379","volume":"275","author":"T Nakashima","year":"2000","unstructured":"Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H et al (2000) Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275(3):768\u2013775","journal-title":"Biochem Biophys Res Commun"},{"key":"2104_CR26","doi-asserted-by":"publisher","first-page":"R476","DOI":"10.1186\/ar1694","volume":"7","author":"S Nakayamada","year":"2005","unstructured":"Nakayamada S, Kurose H, Saito K, Mogami A, Tanaka Y (2005) Small GTP-binding protein Rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts. Arthritis Res Ther 7:R476-484","journal-title":"Arthritis Res Ther"},{"issue":"04","key":"2104_CR102","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4103\/2278-330X.119895","volume":"02","author":"P Narayanan","year":"2013","unstructured":"Narayanan P (2013) Denosumab: a comprehensive review. South Asian J Cancer 02(04):272\u2013277","journal-title":"South Asian J Cancer"},{"issue":"2","key":"2104_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.immuni.2017.01.004","volume":"46","author":"HN Nguyen","year":"2017","unstructured":"Nguyen HN, Noss EH, Mizoguchi F, Huppertz C, Wei KS, Watts GFM et al (2017) Autocrine loop involving IL-6 family member LIF, LIF receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators. Immunity 46(2):220\u2013232","journal-title":"Immunity"},{"key":"2104_CR101","doi-asserted-by":"crossref","unstructured":"Nirk EL, Reggiori F, Mauthe M (2020) Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med 12(8)","DOI":"10.15252\/emmm.202012476"},{"key":"2104_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.209","volume":"9","author":"S Onuora","year":"2013","unstructured":"Onuora S (2013) Inflammation: a new path to treating arthritis? Nat Rev Rheumatol 9:2","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2104_CR117","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T et al (2014) Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 73(1):198\u2013206","journal-title":"Ann Rheum Dis"},{"key":"2104_CR35","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1136\/ard-2022-222605","volume":"81","author":"Y Qin","year":"2022","unstructured":"Qin Y, Cai ML, Jin HZ, Huang W, Zhu C, Bozec A et al (2022) Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-\u03b1-mediated ERK1\/2 and JAK-STAT1 pathways. Ann Rheum Dis 81:1504\u20131514","journal-title":"Ann Rheum Dis"},{"key":"2104_CR49","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/13543776.18.7.723","volume":"18","author":"LD Quan","year":"2008","unstructured":"Quan LD, Thiele GM, Tian J, Wang D (2008) The development of novel therapies for rheumatoid arthritis. Expert Opin Ther Pat 18:723\u2013738","journal-title":"Expert Opin Ther Pat"},{"key":"2104_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112857","author":"AF Radu","year":"2021","unstructured":"Radu AF, Bungau SG (2021) Management of rheumatoid arthritis: an overview. Cells. https:\/\/doi.org\/10.3390\/cells10112857","journal-title":"Cells"},{"key":"2104_CR94","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2147\/DDDT.S100302","volume":"11","author":"MG Raimondo","year":"2017","unstructured":"Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG (2017) Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug des Devel Ther 11:1593\u20131603","journal-title":"Drug des Devel Ther"},{"key":"2104_CR10","doi-asserted-by":"crossref","unstructured":"Safiri S, Kolahi AA, Hoy D, Buchbinder R, Mansournia MA, Bettampadi D et al (2020) Global, regional, and national burden of neck pain in the general population, 1990\u20132017: Systematic analysis of the Global Burden of Disease Study 2017. BMJ 368","DOI":"10.1136\/bmj.m791"},{"key":"2104_CR25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2007.074278","volume":"67","author":"G Schett","year":"2008","unstructured":"Schett G, Zwerina J, Firestein G (2008) The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 67:909\u2013916","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"2104_CR93","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ (2017) Tocilizumab: a review in rheumatoid arthritis. Drugs 77(17):1865\u20131879","journal-title":"Drugs"},{"issue":"1","key":"2104_CR89","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/1744666X.2019.1544892","volume":"15","author":"L Serhal","year":"2019","unstructured":"Serhal L, Edwards CJ (2019) Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 15(1):13\u201325","journal-title":"Expert Rev Clin Immunol"},{"issue":"42","key":"2104_CR64","doi-asserted-by":"publisher","first-page":"27467","DOI":"10.1074\/jbc.273.42.27467","volume":"273","author":"T Shalom-Barak","year":"1998","unstructured":"Shalom-Barak T, Quach J, Lotz M (1998) Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem 273(42):27467\u201327473","journal-title":"J Biol Chem"},{"key":"2104_CR99","doi-asserted-by":"crossref","unstructured":"Smedeg\u00e5rd G, Bj\u00f6rk J (1995) Sulphasalazine: Mechanism of action in rheumatoid arthritis. Rheumatology XXXIV(suppl_2):7\u201315","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.7"},{"key":"2104_CR51","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016b) Rheumatoid arthritis. Lancet 388:2023\u20132038","journal-title":"Lancet"},{"issue":"10055","key":"2104_CR107","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016c) Rheumatoid arthritis. Lancet 388(10055):2023\u20132038","journal-title":"Lancet"},{"issue":"1","key":"2104_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P et al (2016a) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75(1):3\u201315","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2104_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2022","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D et al (2022) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2104_CR18","doi-asserted-by":"publisher","first-page":"S685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):S685-699","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2104_CR61","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1006\/cyto.2000.0753","volume":"12","author":"S Stea","year":"2000","unstructured":"Stea S, Visentin M, Granchi D, Ciapetti G, Donati ME, Sudanese A et al (2000) Cytokines and osteolysis around total hip prostheses. Cytokine 12(10):1575\u20131579","journal-title":"Cytokine"},{"key":"2104_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1365-2796.2010.02218.x","volume":"267","author":"RH Straub","year":"2010","unstructured":"Straub RH, Cutolo M, Buttgereit F, Pongratz G (2010) Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med 267:543\u2013560","journal-title":"J Intern Med"},{"key":"2104_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.semarthrit.2015.04.014","volume":"45","author":"RH Straub","year":"2015","unstructured":"Straub RH, Cutolo M, Pacifici R (2015) Evolutionary medicine and bone loss in chronic inflammatory diseases-a theory of inflammation-related osteopenia. Semin Arthritis Rheum 45:220\u2013228","journal-title":"Semin Arthritis Rheum"},{"key":"2104_CR44","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.joca.2020.02.027","volume":"28","author":"K Sun","year":"2020","unstructured":"Sun K, Luo J, Guo J, Yao X, Jing X, Guo F (2020) The PI3K\/AKT\/mTOR signaling pathway in osteoarthritis: a narrative review. Osteoarthritis Cartilage 28:400\u2013409","journal-title":"Osteoarthritis Cartilage"},{"key":"2104_CR17","doi-asserted-by":"publisher","first-page":"VI12","DOI":"10.1093\/rheumatology\/keab609","volume":"60","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y (2021) Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology 60:VI12-20","journal-title":"Rheumatology"},{"issue":"3","key":"2104_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00033-X","volume":"6","author":"The Lancet Rheumatology","year":"2024","unstructured":"The Lancet Rheumatology (2024) JAK inhibitors\u2014Friend or Foe? Lancet Rheumatol 6(3):e129","journal-title":"Lancet Rheumatol"},{"key":"2104_CR23","doi-asserted-by":"crossref","unstructured":"Theodosiou A, Ashworth A (2002) Protein family review MAP kinase phosphatases. Genome Biol 3(7)","DOI":"10.1186\/gb-2002-3-7-reviews3009"},{"key":"2104_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093208","author":"CA Wagenaar","year":"2021","unstructured":"Wagenaar CA, van de Put M, Bisschops M, Walrabenstein W, de Jonge CS, Herrema H et al (2021) The effect of dietary interventions on chronic inflammatory diseases in relation to the microbiome: a systematic review. Nutrients. https:\/\/doi.org\/10.3390\/nu13093208","journal-title":"Nutrients"},{"issue":"2","key":"2104_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/ard.2005.037929","volume":"65","author":"JG Walker","year":"2006","unstructured":"Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D et al (2006) Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 65(2):149\u2013156","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2104_CR71","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1172\/JCI200523394","volume":"115","author":"S Wei","year":"2005","unstructured":"Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL (2005) IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115(2):282","journal-title":"J Clin Invest"},{"key":"2104_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/biom11101444","author":"RH Whitaker","year":"2021","unstructured":"Whitaker RH, Cook JG (2021) Stress relief techniques: P38 MAPK determines the balance of cell cycle and apoptosis pathways. Biomolecules. https:\/\/doi.org\/10.3390\/biom11101444","journal-title":"Biomolecules"},{"issue":"1","key":"2104_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/417048","volume":"66","author":"GC Williams","year":"1991","unstructured":"Williams GC, Nesse RM (1991) The dawn of Darwinian medicine. Q Rev Biol 66(1):1\u201322","journal-title":"Q Rev Biol"},{"issue":"1","key":"2104_CR78","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/art.21537","volume":"54","author":"PKK Wong","year":"2006","unstructured":"Wong PKK, Quinn JMW, Sims NA, Van Nieuwenhuijze A, Campbell IK, Wicks IP (2006) Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 54(1):158\u2013168","journal-title":"Arthritis Rheum"},{"key":"2104_CR37","doi-asserted-by":"crossref","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q et al (2023) Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther 8","DOI":"10.1038\/s41392-023-01468-7"},{"issue":"5","key":"2104_CR63","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/sj.gt.3302192","volume":"11","author":"SY Yang","year":"2004","unstructured":"Yang SY, Wu B, Mayton L, Mukherjee P, Robbins PD, Evans CH et al (2004) Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debris-induced osteolysis. Gene Ther 11(5):483\u2013491","journal-title":"Gene Ther"},{"key":"2104_CR27","first-page":"14","volume":"29","author":"M Yan","year":"1994","unstructured":"Yan M, Dalt T, Deak JC, Kyrlaklst JM, Zon LI, Woodgettt JR et al (1994) Alessi DR. Biochem J 29:14","journal-title":"Biochem J"},{"issue":"4","key":"2104_CR122","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41584-021-00585-3","volume":"17","author":"MM Zaiss","year":"2021","unstructured":"Zaiss MM, Joyce Wu HJ, Mauro D, Schett G, Ciccia F (2021) The gut-joint axis in rheumatoid arthritis. Nat Rev Rheumatol 17(4):224\u2013237","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"2104_CR92","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2217\/imt-2017-0155","volume":"10","author":"S Zhao","year":"2018","unstructured":"Zhao S, Mysler E, Moots RJ (2018) Etanercept for the treatment of rheumatoid arthritis. Immunotherapy 10(6):433\u2013445","journal-title":"Immunotherapy"},{"key":"2104_CR45","unstructured":"Zou L, Zhang G, Liu L, Chen C, Cao X, Cai J (2016) Relationship between PI3K pathway and angiogenesis in CIA rat synovium. Am J Transl Res 8"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02104-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-02104-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02104-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:02:38Z","timestamp":1771639358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-02104-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2104"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-02104-2","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Permission from the Institutional Ethical Committee does not apply to this review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate."}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}